Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis.
Akalay I, Janji B, Hasmim M, Noman MZ, André F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, Sabbah M, Tan TZ, Keira JH, Hung NT, Thiery JP, Mami-Chouaib F, Chouaib S. Akalay I, et al. Among authors: bertheau p. Cancer Res. 2013 Apr 15;73(8):2418-27. doi: 10.1158/0008-5472.CAN-12-2432. Epub 2013 Feb 22. Cancer Res. 2013. PMID: 23436798
BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, de Cremoux P. Hamy AS, et al. Among authors: bertheau p. Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3. Breast Cancer Res Treat. 2016. PMID: 27592112
Distinct tumor protein p53 mutants in breast cancer subgroups.
Dumay A, Feugeas JP, Wittmer E, Lehmann-Che J, Bertheau P, Espié M, Plassa LF, Cottu P, Marty M, André F, Sotiriou C, Pusztai L, de Thé H. Dumay A, et al. Among authors: bertheau p. Int J Cancer. 2013 Mar 1;132(5):1227-31. doi: 10.1002/ijc.27767. Epub 2012 Sep 1. Int J Cancer. 2013. PMID: 22886769
COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.
DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I. DE Cremoux P, et al. Among authors: bertheau p. Anticancer Res. 2018 Mar;38(3):1485-1490. doi: 10.21873/anticanres.12375. Anticancer Res. 2018. PMID: 29491076 Clinical Trial.
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients.
de Cremoux P, Valet F, Gentien D, Lehmann-Che J, Scott V, Tran-Perennou C, Barbaroux C, Servant N, Vacher S, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Asselain B, Marty M, Spyratos F. de Cremoux P, et al. Among authors: bertheau p. BMC Cancer. 2011 Jun 1;11:215. doi: 10.1186/1471-2407-11-215. BMC Cancer. 2011. PMID: 21631949 Free PMC article. Clinical Trial.
p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H. Bertheau P, et al. Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Breast. 2013. PMID: 24074787 Free article. Review.
[Ductal carcinoma in situ diagnosis: 3 French national guidelines].
Cutuli B, Tunon De Lara C, Arnaud A, Bertheau P, Boulanger L, Boute V, Ceugnart L, Chauvet MP, Coutant C, De Cremoux P, Fourquet A, Hennequin C, Lesieur A, Lesur A, Lévy L, Vincent-Salomon A, Besnard S, Belorgey C. Cutuli B, et al. Among authors: bertheau p. Ann Pathol. 2016 Jun;36(3):166-73. doi: 10.1016/j.annpat.2016.03.012. Epub 2016 May 25. Ann Pathol. 2016. PMID: 27236350 French.
Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.
Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E, de Cremoux P, de Bazelaire C, Albiter M, Giacchetti S, Cuvier C, Janin A, Espié M, de Thé H, Bertheau P. Lehmann-Che J, et al. Among authors: bertheau p. Breast Cancer Res. 2013 May 11;15(3):R37. doi: 10.1186/bcr3421. Breast Cancer Res. 2013. PMID: 23663520 Free PMC article.
150 results